September 2023 in “Drugs in context” Baricitinib is a promising treatment for alopecia areata.
September 2022 in “Journal of the American Academy of Dermatology” The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
400 citations
,
October 1995 in “Journal of clinical oncology” Docetaxel is effective against various cancers but mainly causes neutropenia.
June 2023 in “Value in Health” Alopecia areata treatments often cause headaches and infections, highlighting the need for safer options.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.
2 citations
,
November 2022 in “Biosensors” A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
December 2025 in “Indian Journal of Case Reports” Stopping azathioprine improved hair loss and bone marrow issues.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
December 2024 in “PubMed” Freezia cream helps regrow hair in people with Alopecia Areata.
January 2024 in “International Journal of Dermatology Research” PRP is more effective than triamcinolone for treating alopecia areata.
1 citations
,
November 2023 in “Skin Appendage Disorders” 308 nm excimer lamp therapy is effective for alopecia areata but less so for severe cases.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
17 citations
,
January 2021 in “Agrobiological Records” Allethrin caused harmful effects and organ damage in rats, worsening with higher doses and longer exposure.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
7 citations
,
May 2010 in “Journal of Dermatological Treatment” A man with multiple autoimmune diseases developed liver injury from azathioprine, but his liver improved after stopping the drug.
3 citations
,
December 2015 in “Musculoskeletal care” Many patients on methotrexate experience significant side effects but still continue the medication.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
9 citations
,
December 2018 in “Cutaneous and Ocular Toxicology” Combined BRAF and MEK treatment increases rash risk but reduces other skin issues compared to BRAF alone.
11 citations
,
November 2013 in “Skin Pharmacology and Physiology” Azelaic Acid is effective and safe for treating adult female acne, with few side effects.
January 2023 in “JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH” Combining injections with lotion is more effective for hair regrowth in alopecia areata than using the lotion alone.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
10 citations
,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.